|Bid||93.00 x 800|
|Ask||93.89 x 900|
|Day's Range||90.25 - 94.24|
|52 Week Range||28.82 - 95.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 17, 2018 - Jul 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.47|
In this article, I will take a look at Sarepta Therapeutics Inc’s (NASDAQ:SRPT) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / U.S. markets rallied on Friday, despite trade uncertainties and weak employment data, as a surge in Apple led to strong gains by the tech sector. The Dow Jones ...
"Our partnership with Invitae is important to advancing our clinical study objectives across our entire RNA-based platform," said Doug Ingram, Sarepta's President and CEO. DMD is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500 – 5,000 males worldwide and is caused by a change or mutation in the gene that encodes instructions for dystrophin.
Sarepta Therapeutics (SRPT) has been winning over investors with rising sales of its drug to treat Duchenne muscular dystrophy, or DMD, and a promising pipeline of drugs targeted at the fatal muscle-wasting disease. The company’s shares rose $11.58, or almost 15%, to $89.75 on Friday and hit a new 52-week high of $90.99 after the Cambridge, Mass., biotech reported first-quarter results after trading closed on Thursday. Sarepta now is valued at nearly $6 billion.
Sarepta rocketed to an 18-year high Friday amid furor surrounding its newest treatments for a fatal disease called Duchenne muscular dystrophy.
Shares of Sarepta Therapeutics (SRPT) are up 11.5% to $87.20 Friday after hitting a 52-week high of $88.24 earlier in the day. The biotechnology company had reported results after the close of trading Thursday that were in line with market expectations. It’s unclear what’s driving up the stock today, but it could be optimism about Sarepta’s gene-therapy program for Duchenne muscular dystrophy, a fatal muscle-wasting disease affecting boys.
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / U.S. markets were mixed Thursday as investors appear to be awaiting monthly jobs data due to be released on Friday. The Dow Jones Industrial Average gained 0.02 ...
Sarepta Therapeutics on Thursday reported a loss of 28 cents per share on $64.6 million in sales for its first quarter.
Sarepta Therapeutics Inc. shares fell nearly 5% late Thursday after the biopharma company reported a wider-than-expected adjusted first-quarter loss and sales also missed targets. Sarepta said it lost $35.4 million, or 55 cents a share, in the quarter, versus earnings of $84.1 million, or $1.50 a share, in the year-ago period. Adjusted for one-time items, Sarepta lost $17.9 million, or 28 cents a share, compared with a net loss of $31.4 million, or 57 cents a share, a year ago.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 55 cents. Losses, adjusted for stock option expense and non-recurring costs, came to 28 cents per share. The results ...
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that it has entered into an exclusive partnership with Myonexus Therapeutics, Inc., a clinical-stage biotechnology company developing transformative gene therapies for various forms of Limb-girdle muscular dystrophies (LGMDs). Myonexus’ five LGMD gene therapy candidates target the most severe and common forms of the disease and include three clinical and two pre-clinical stage programs. The most advanced of Myonexus’ programs, MYO-101, aims to treat LGMD2E, also known as beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss, inflammation and muscle fiber replacement with fat and fibrotic tissue.
--First quarter 2017 EXONDYS 51 ® total net revenues of $64.6 million--. --Sarepta signs exclusive partnership and buy-out option with Myonexus Therapeutics; pipeline expands from 16 to 21 programs--. ...
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on April 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to forty individuals hired by Sarepta in April 2018. The employees received, in the aggregate, options to purchase 170,959 shares of Sarepta's common stock. The options have an exercise price of $76.36 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2018.
NEW YORK, April 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
CAMBRIDGE, Mass., April 23, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
Sarepta Therapeutics (SRPT) posted $231.9 million in operating activities in fiscal 2017 compared with $245.8 million in fiscal 2016. This decrease of $13.8 million in fiscal 2017 was primarily due to a decrease of $91.6 million in a net loss. This trend was driven by higher product revenues of Exondys and a decrease in research and development expenses due to capitalization of inventory.
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) generated revenues of $154.5 million in fiscal 2017 compared with $5.4 million in fiscal 2016. The substantial increase in revenues shows the increasing demand for the product.
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics’ (SRPT) Exondys was granted accelerated approval by the FDA in September 2016. Sarepta Therapeutics’ golodirsen is an exon 53 skipping drug candidate.
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Markets are looking shaky, but first ... crush the shorts. Yahoo Finance's Seana Smith and Jared Blikre lay it all out, breaking down the price action in the SPDR S&P 500 ETF (SPY).